Celldex Q2 net loss $30.5M ($0.65/sh); Phase 2 CSU enrollment complete, topline by YE 2023

Celldex Therapeutics, Inc.

2023-Q2 EPS reported -$1.27 revenue$1,234,000

Net loss of $30.5M ($0.65/sh) for Q2 2023 vs $36.0M ($0.77/sh) in Q2 2022; cash $252.7M.
Phase 2 CSU enrollment completed with 208 patients, 25% above target; topline data expected by YE 2023.
Phase 1b PN data planned for Q4 2023; Phase 2 EoE initiated, first patient dosed in July.
R&D expenses increased to $26.3M from $20.7M YoY, driven by barzolvolimab costs.
Cash runway sufficient through 2025 to fund planned Phase 2 studies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Celldex Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the second quarter of 2023.

View on SEC.gov

Browse all earnings releases →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-005101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.